Response to Mivacurium in Patients Carrying the K Variant in the Butyrylcholinesterase Gene
Open Access
- 1 March 2005
- journal article
- conference paper
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 102 (3) , 503-508
Abstract
Background: Mivacurium is hydrolyzed by the butyrylcholinesterase enzyme, and patients with hereditary changes of the enzyme often have prolonged duration of action of mivacurium. In this study, the authors investigated the significance of the most commonly occurring variant, the Kalow (K) variant, established using DNA analysis, for the response to mivacurium. Methods: A total of 58 patients carrying either the wild-type butyrylcholinesterase or different combinations of the atypical (A) variant and the K variant were included. Patients who were homozygous for the A variant were given 0.03 mg/kg mivacurium. All other patients received 0.2 mg/kg mivacurium. The neuromuscular block was measured using train-of-four nerve stimulation and mechanomyography. Genotyping was performed with complete nucleotide sequencing. Results: Heterozygosity of the K variant prolonged the time to train-of-four 0.70 from 26.6 to 34.5 min (30%; not significant) as compared with the wild type. Heterozygosity of the K variant linked to the A variant prolonged the corresponding time from 32 to 42.7 min (33%; P = 0.03) as compared with patients who were heterozygous for solely an A allele. For eight patients who were homozygous for both the A and K variants, the time to 25% recovery was 78-89 min as compared with 44-57 min in patients who were homozygous for the A variant or had only one linked K variant. Conclusion: The K variant prolongs the duration of action of mivacurium. The current results indicate that the effect is modest when the K variant occurs heterozygously with the wild type or the A variant but is marked in patients who are homozygous for both the A and K variants.Keywords
This publication has 28 references indexed in Scilit:
- Frequency and enzyme activity of the butyrylcholinesterase K-variant in a Turkish populationEuropean Journal of Clinical Pharmacology, 2004
- Response to Mivacurium in a Patient Compound Heterozygous for a Novel and a Known Silent Mutation in the Butyrylcholinesterase GeneAnesthesiology, 2001
- Prolonged mivacurium neuromuscular block in childrenPediatric Anesthesia, 1998
- Markedly Prolonged Paralysis After Mivacurium in a Patient Apparently Heterozygous for the Atypical and Usual Pseudocholinesterase Alleles by Conventional Biochemical TestingAnesthesia & Analgesia, 1997
- Detection of the Plasma Cholinesterase K Variant by PCR Using an Amplification-Created Restriction SiteHuman Heredity, 1996
- Prolonged Neuromuscular Block from Mivacurium in Two Patients with Cholinesterase DeficiencyAnesthesia & Analgesia, 1993
- Mivacurium‐induced neuromuscular blockade in patients with atypical plasma cholinesteraseActa Anaesthesiologica Scandinavica, 1993
- Prolonged Neuromuscular Block After MivacuriumAnesthesia & Analgesia, 1993
- Influence of plasma cholinesterase activity on recovery from mivacurium-induced neuromuscular blockade in phenotypically normal patientsActa Anaesthesiologica Scandinavica, 1992
- Refinement of the localization of human butyrylcholinesterase to chromosome 3q26.1-q26.2 using a PCR-derived probeGenomics, 1991